Genetic Counseling And Testing For Alzheimer Disease
Publication Date: May 1, 2011
Last Updated: March 14, 2022
GUIDELINES
Pediatric testing for AD should not occur. Prenatal testing for AD is not advised if the patient intends to continue a pregnancy with a mutation.
6731
Genetic testing for AD should only occur in the context of genetic counseling (in-person or through videoconference) and support by someone with expertise in this area.
-
Symptomatic patients: Genetic counseling for symptomatic patients should be performed in the presence of the individual's legal guardian or family member.
-
Asymptomatic patients: A protocol based on the International Huntington Association and World Federation of Neurology Research Group on Huntington's Chorea Guidelines is recommended.
6731
DTC APOE testing is not advised.
6731
A ≥3-generation family history should be obtained, with specific attention to the age of onset of any neurologic and/or psychiatric symptoms, type of dementia and method of diagnosis, current ages, or ages at death (especially unaffected relatives), and causes of death. Medical records should be used to confirm AD diagnosis when feasible. The history of additional relatives may prove useful, especially in small families or those with a preponderance of early death that may mask a history of dementia.
6731
A risk assessment should be performed by pedigree analysis to determine whether the family history is consistent with EOAD or LOAD and with autosomal dominant (with or without complete penetrance), familial, or sporadic inheritance.
6731
Patients should be informed that currently there are no proven pharmacologic or lifestyle choices that reduce the risk of developing AD or stop its progression.
6731
The following potential genetic contributions to AD should be reviewed:
<p style="margin-left: 40px;">○ The lifetime risk of AD in the general population is approximately 10–12% in a 75–80-year lifespan.</p>
<p style="margin-left: 40px;">○ The effect(s) of ethnicity on risk is still unclear.</p>
<p style="margin-left: 40px;">○ Although some genes are known, there are very likely others (susceptibility, deterministic, and protective) whose presence and effects are currently unknown.</p>
6731
For families in which an autosomal dominant AD gene mutation is a possibility
Discuss the risk of inheriting a mutation from a parent affected with autosomal dominant AD is 50%. In the absence of identifying a mutation in apparent autosomal dominant families, risk to offspring could be as high as 50% but may be less.
6731
Testing for genes associated with early-onset autosomal dominant AD should be offered in the following situations:
○ A symptomatic individual with EOAD in the setting of a family history of dementia or in the setting of an unknown family history (e.g., adoption).
○ Autosomal dominant family history of dementia with one or more cases of EOAD.
○ A relative with a mutation consistent with EOAD (currently PSEN1/2 or APP).
6731
Discuss the likelihood of identifying a mutation in PSEN1, PSEN2, or APP, noting that current experience indicates that this likelihood decreases with lower proportions of affected family members and/or older ages of onset.
6731
Ideally, an affected family member should be tested first. If no affected family member is available for testing and an asymptomatic individual remains interested in testing despite counseling about the low likelihood of an informative result (a positive result for a pathogenic mutation), he/she should be counseled according to the recommended protocol. If the affected relative, or their next of kin, is uninterested in pursuing tested, the option of DNA banking should be discussed.
6731
For families in which autosomal dominant AD is unlikely
Inform them why their family history is consistent with familial or sporadic AD.
6731
Discuss that both sporadic and familial cases can be due to a genetic susceptibility. Risk estimates are only available for first-degree relatives of an affected individual in sporadic or familial cases.
6731
Genetic testing for susceptibility loci (e.g., APOE) is not clinically recommended due to limited clinical utility and poor predictive value. If a patient wishes to pursue testing despite genetic counseling and recommendations to the contrary, testing may be considered at the clinician's discretion. Testing performed should follow the HD genetic testing guidelines, with emphasis on genetic counseling with a qualified clinician. As such, DTC genetic testing is not advised.
6731
Motives and considerations for pursuing genetic testing should be explored. This counseling should be an exploration of personal experiences, value and beliefs, and personal and family needs. Genetic testing should be discussed within the context of adapting to familial risk and when clients feel compelled to learn a more refined estimate of their risks to enhance their quality of life. As part of this, it is helpful to lead the individual through the scenario of receiving a positive test result and a negative test result, having them assess the ways these results would positively or adversely impact their psyche, life plans, and relationships.
○ Symptomatic patients: Because genetic testing of a symptomatic individual is typically requested by a relative concerned about his risk, the counselor must remain alert to any potential conflicts of interest, such as lack of interest of the symptomatic patient or of other at-risk family members. If the symptomatic patient gives any inclination of being averse to testing, it is not recommended. Instead, DNA banking should be explored.
If there is disagreement within the family regarding whether testing should be performed, a family meeting is strongly encouraged (with or without the genetic counselor present). A family meeting would allow all interested parties to discuss the potential impact of the genetic testing on the family, how test results will be communicated, and how to respect the rights of those family members who do not wish to know the results.
6731
Genetic testing: In the event testing is chosen, the following is recommended:
○ Asymptomatic patients should receive a neurologic examination to assess for signs of dementia and to establish a baseline.
○ Assess patient's and any accompanying family member's psychological state of mind. In the case of presymptomatic testing, a consultation with a psychologist/psychiatrist may be recommended for the patient as part of the HD testing approach.
6731
If the patient seems to suffer from, or is potentially at risk for significant psychological/psychiatric problems, consider a psychotherapy referral before testing.
6731
If the psychological assessment suggests testing is not in the person's current best interest (e.g., untreated depression or recent death), these reservations should be shared openly, and an agreement should be made to revisit testing once the underlying condition and/or stressors have diminished. A referral for psychotherapy may also be appropriate.
○ Assess and review the psychosocial impact of testing on the patient and his/her family.
6731
Reinforce results cannot be “taken back” (although an individual can decide not to learn his or her test results after having the test performed.)
○ Discuss testing logistics, associated costs, and possible outcomes.
6731
For EOAD genes, determine best approach to testing for patient (i.e., stepwise testing beginning with PSEN1 as the most likely gene or ordering a panel).
6731
Discuss where results will be kept (e.g., medical record).
6731
Determine who will accompany the patient to the result session for support.
6731
Discuss possible test outcomes (positive, negative, or variant of uncertain significance). If testing for
APOE, consider whether you will report other disease risk implications. If so, these should be included in the discussion of test outcomes with the patient. Also, it should be reiterated that
APOE is a susceptibility gene and is not a predictive test. Thus, individuals with no copies of the ε4 allele still face a 2–4-fold increased lifetime risk of developing AD if they have a first-degree relative with AD.
○ Assist the patient and participating family members with informed decision making regarding whom, if anyone, they plan to share the results with and how. Inform about the importance of discretion when discussing genetic testing and results.
○ Discuss the potential impact of genetic test results on insurance, and the benefits and limitations of existing state and federal genetic discrimination legislation.
○ Obtain informed consent for all genetic testing for AD.
○ After results disclosure, revisit the individual's plans regarding with whom and how the results will be shared.
○ Arrange for a follow-up plan to “check in” with the patient and, if relevant, participating family member, and determine whether another genetic counseling session would be beneficial to the patient and/or the patient's partner/family members/friends.
6731
Discuss the availability and status of AD research and/or DNA banking.
6731
Title
Genetic Counseling And Testing For Alzheimer Disease
Authoring Organization
National Society of Genetic Counselors
Publication Month/Year
May 1, 2011
Last Updated Month/Year
January 8, 2024
External Publication Status
Published
Country of Publication
US
Document Objectives
This practice guideline provides clinicians with a framework for assessing their patients' genetic risk for Alzheimer disease, identifying which individuals may benefit from genetic testing, and providing the key elements of genetic counseling for AD.
Target Patient Population
Patients with genetic risk for Alzheimer disease
Inclusion Criteria
Female, Male, Adult, Older adult
Health Care Settings
Ambulatory, Long term care, Outpatient
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Counseling, Assessment and screening, Diagnosis, Management
Diseases/Conditions (MeSH)
D005820 - Genetic Testing, D005817 - Genetic Counseling, D000544 - Alzheimer Disease
Keywords
genetic testing, Alzheimer disease, genetic counseling